Investors / United States / Dynamk Capital
Dynamk Capital
Venture capital · New York, NY, United States · North America
Dynamk Capital is an investment firm focused on life sciences, with a fund called the Dynamk Capital Life Sciences Fund. Its site highlights portfolio company news in biotech tools, cell therapy and diagnostics.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechcell therapydiagnosticsbioprocessing
Your fit with Dynamk Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsDynamk Capital lists 10 checked portfolio companies on its own site. Its largest theme is Healthcare & Biotech (100%). 50% of its companies are based in United Kingdom. It invests most often alongside ARCH Venture Partners, Avego and BlueYard Capital.
No funding round on record names Dynamk Capital yet, so the figures come from its portfolio page.
Round figures show recent activity, not Dynamk Capital's whole history. Rounds on record name 0 companies; its own site lists 10. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 23th | 10 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers10100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Dynamk Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
10 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alpenglow Biosciences combines 3D light-sheet imaging, automated volumetric data processing, and AI-powered analysis to quantify cells, structures, and spatial relationships for drug development, diagnostics, and AI. | Healthcare & Biotech | Portfolio page | ||
| The company develops and sells synthetic biology products for human health, including cells and assays for various diseases and applications. | Healthcare & Biotech | Portfolio page | ||
| CellFE creates a microfluidic-based gene editing technology for cell therapy manufacturing | Healthcare & Biotech | Portfolio page | ||
| Curi Bio develops and provides 3D tissue models and biosystems for drug discovery and development. | Healthcare & Biotech | Portfolio page | ||
| Envisagenics discovers therapeutic targets in oncology and neurodegeneration using an AI platform that targets RNA splicing | Healthcare & Biotech | Portfolio page | ||
| Lucid Scientific develops and sells a cellular oxygen consumption rate monitoring system called Resipher. | Healthcare & Biotech | Portfolio page | ||
| RoosterBio develops and provides human mesenchymal stem cells and related products and services for therapeutic technologies. | Healthcare & Biotech | Portfolio page | ||
| Vectron Biosolutions develops tailor-made expression vectors for microbial protein production for its customers. | Healthcare & Biotech | Portfolio page | ||
| Virica Biotech develops and provides small molecule cell enhancers called Viral Sensitizers to improve manufacturing productivity and reduce costs in cell and gene therapies | Healthcare & Biotech | Portfolio page | ||
| The company develops and manufactures cell therapy platforms for solid tumor therapies. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- dynamk.vc
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Companies checked
- 10
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Dynamk Capital's profile as data
Pull Dynamk Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/dynamk.vc
# also
GET /v1/firms/dynamk.vc/portfolio
GET /v1/firms/dynamk.vc/coinvestors
GET /v1/firms/dynamk.vc/news